Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

29.6%

8 terminated/withdrawn out of 27 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

44%

7 of 16 completed trials have results

Key Signals

1 recruiting7 with results5 withdrawn

Enrollment Performance

Analytics

Phase 2
12(48.0%)
Phase 1
7(28.0%)
N/A
6(24.0%)
25Total
Phase 2(12)
Phase 1(7)
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT04291066Phase 2Completed

Prospective Analysis of the Use of N-Acetylcysteine and Vitamins in the Treatment of TBI in Geriatric Patients

Role: lead

NCT03915444Phase 2Completed

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Role: lead

NCT03138720Phase 2Completed

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Role: lead

NCT05175521Not ApplicableCompleted

Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine

Role: lead

NCT05068752Phase 2Completed

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Role: lead

NCT07463599Phase 1Recruiting

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Role: lead

NCT06076837Phase 1Active Not Recruiting

The Seven Trial: Exploiting the Unfolded Protein Response

Role: lead

NCT02754726Phase 2Completed

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Role: lead

NCT04669197Phase 2Active Not Recruiting

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Role: lead

NCT05229588Phase 2Completed

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

Role: lead

NCT05004025Phase 1Completed

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Role: lead

NCT05556447Not ApplicableWithdrawn

Internet-delivered Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Role: collaborator

NCT03606642Phase 2Terminated

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

Role: lead

NCT03415854Phase 2Completed

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Role: lead

NCT03714555Phase 2Terminated

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Role: lead

NCT05216120Phase 2Withdrawn

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Role: lead

NCT03410030Phase 1Completed

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Role: lead

NCT04275830Not ApplicableCompleted

The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients

Role: collaborator

NCT05374876Not ApplicableCompleted

Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy

Role: lead

NCT04339426Phase 2Terminated

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Role: lead